Who are Vizamyl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqembi, Aduhelm, Neuraceq, Amyvid, M.V.I. Pediatric, Calcium Disodium Versenate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flutemetamol-18f.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vizamyl — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vizamyl (Flutemetamol (18F)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioactive Diagnostic Agent [EPC]. Area: Immunology.

marketed Radioactive Diagnostic Agent [EPC] Amyloid beta A4 protein Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Vizamyl (Flutemetamol (18F)) — GE HealthCare. Vizamyl works by binding to amyloid beta A4 protein in the brain, allowing for visualization of amyloid deposits in PET imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vizamyl TARGET	Flutemetamol (18F)	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2013-01-01
Leqembi	LECANEMAB	Eisai	marketed	Amyloid Beta-directed Antibody [EPC]	Amyloid beta A4 protein	2023-01-01
Aduhelm	ADUCANUMAB	Biogen	marketed	Amyloid Beta-directed Antibody	Amyloid beta A4 protein	2021-01-01
Neuraceq	FLORBETABEN F18	Piramal Imaging	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2014-01-01
Amyvid	FLORBETAPIR F 18	Avid Radiopharms Inc	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2012-01-01
M.V.I. Pediatric	RETINOL	Pfizer	marketed	Vitamin A	Amyloid beta A4 protein	1953-01-01
Calcium Disodium Versenate	EDETIC ACID	Medicis	marketed	Anti-coagulant	Amyloid beta A4 protein	1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-30 — Amyvid · 8506929 · US
2027-04-30 — Amyvid · 7687052 · US
2028-09-16 — Vizamyl · 8916131 · US
2029-03-18 — Neuraceq · 7807135 · US

Sponsor landscape (Radioactive Diagnostic Agent [EPC] class)

· 6 drugs in this class
GE HealthCare · 3 drugs in this class
Blue Earth · 2 drugs in this class
Avid Radiopharms Inc · 2 drugs in this class
Ge Hlthcare Inc · 2 drugs in this class
Ge Healthcare · 1 drug in this class
Ge Hlthcare · 1 drug in this class
Lantheus Medical Imaging · 1 drug in this class
Life Molecular · 1 drug in this class
Mcprf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vizamyl — Competitive Intelligence Brief. https://druglandscape.com/ci/flutemetamol-18f. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing